Determining the feasibility of linked claims and vaccination data for a COVID-19 vaccine pharmacoepidemiological study in Germany—RiCO feasibility study protocol

Determining the feasibility of linked claims and vaccination data for a COVID-19 vaccine pharmacoepidemiological study in Germany—RiCO feasibility study protocol

Introduction In Germany, there has been no population-level pharmacoepidemiological study on the safety of the COVID-19 vaccines. One factor preventing such a study so far relates to challenges combining the different relevant data bodies on vaccination with suitable outcome data, specifically statu...

Full description

Bibliographic Details
Main Authors: Peter Ihle, Brigitte Keller-Stanislawski, Ingo Meyer, Nina Timmesfeld, Robin Denz, Katherina Meiszl, Katrin Scholz, Doris Oberle, Ursula Drechsel-Bäuerle, Hans H Diebner
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/14/12/e086074.full

Internet

https://bmjopen.bmj.com/content/14/12/e086074.full

Similar Items